Serial No. 09/900,575 Filed: 6 July 2001

In the Claims:

- 1. (Currently Amended) An isolated immunogenic polypeptide comprising residues 26 to 186 of SEQ ID NO: 29, wherein said polypeptide induces an antibody response that recognizes the polypeptide SEQ ID NO: 29.
- 2. (Currently Amended) The An isolated immunegenic polypeptide of claim 1 comprising the N-terminal two thirds amino acids 1 to 186 of SEQ ID NO: 29, wherein said polypeptide induces an antibody response that recognizes the polypeptide SEQ ID NO: 29.
- 3. (Currently Amended) The An isolated immunogenic polypeptide of claim 1 wherein said polypeptide comprises comprising the amino acid sequence of SEQ ID NO: 29.
- 4. (Withdrawn) The immunogenic polypeptide of claim 1 wherein said sequence is SEQ ID NO: 55.
- 5. (Withdrawn) The immunogenic polypeptide of claim 2 wherein said sequence is SEQ ID NO: 55.
- 6. (Withdrawn) The immunogenic polypeptide of claim 3 wherein said sequence is SEQ ID NO: 55.
 - 7. (Withdrawn) An isolated polynucleotide encoding a polypeptide of claim 1.
 - 8. (Withdrawn) An isolated polynucleotide encoding a polypeptide of claim 3.

S rial No. 09/900,575 Filed: 6 July 2001

- 9. (Withdrawn) An isolated polynucleotide encoding a polypeptide of claim 6.
- 10. (Currently Amended) A vaccine composition comprising an immunogenically effective amount of an immunogenic the polypeptide of claims 1, 2, or 3, wherein said immunogenic polypeptide is in a pharmacologically pharmacoutically acceptable carrier.
- 11. (Withdrawn) A vaccine composition comprising an immunogenically effective amount of an immunogenic polypeptide of claims 4, 5, or 6, wherein said immunogenic polypeptide is in a pharmacologically acceptable carrier.
- 12. (Withdrawn) A vaccine composition comprising an immunogenically effective amount of an immunogenic polypeptide of claims 6, wherein said immunogenic polypeptide is in a pharmacologically acceptable carrier.
- 13. (Withdrawn) An antibody that binds to a polypeptide having an amino acid sequence selected from SEQ ID NO: 23 to 45, and 55.
- 14. (Withdrawn) The antibody of claim 13 wherein said antibody is a monoclonal antibody.
- 15. (Withdrawn) A process for protecting against an enterobacillus-related disease in a patient at risk of contracting such disease comprising administering to said patient an effective amount of the vaccine composition of claim 10, 11 and 12.
- 16. (Withdrawn) The method of claim 15 wherein said disease is a urinary tract infection.

Serial No. 09/900,575 Filed: 6 July 2001

- 17. (Withdrawn) The method of claim 15 wherein the disease is a bladd r infection.
- 18. (Withdrawn) The method of claim 15 wherein the disease is caused by a bacterium of the family Enterobacteriaceae.
 - 19. (Withdrawn) The method of claim 18 wherein the bacterium is E. coli.
- 20. (Withdrawn) A process for treating an enterobacillus-related disease in a patient afflicted therewith comprising administering to said patient animal an effective amount of a vaccine composition of claim 10, 11 or 12.
- 21. (Withdrawn) The method of claim 20 wherein said disease is a urinary tract infection.
- 22. (Withdrawn) The method of claim 20 wherein the disease is a bladder infection.
- 23. (Withdrawn) The method of claim 20 wherein the disease is caused by a bacterium of the family Enterobacteriaceae.
 - 24. (Withdrawn) The method of claim 23 wherein the bacterium is E. coll.
- 25. (Withdrawn) A process for treating an enterobacillus-related disease in a patient afflicted therewith comprising administering to said patient an effective amount of an antibody of claim 13 or 14.
 - 26. (Withdrawn) The method of claim 25 wherein said disease is a urinary tract

Serial No. 09/900,575 Filed: 6 July 2001

infection.

- 27. (Withdrawn) The method of claim 25 wherein the disease is a bladd r infection.
- 28. (Withdrawn) The method of claim 25 wherein the disease is caused by a bacterium of the family Enterobacteriaceae.
 - 29. (Withdrawn) The method of claim 28 wherein the bacterium is E. coli.
- 30. (Withdrawn) A recombinant cell expressing a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to 45, and 55.
- 31. (Withdrawn) The recombinant cell of claim 30 wherein the amino acid sequence is the sequence of SEQ ID NO: 55.
- 32. (Withdrawn) A vector comprising a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to 45, and 55.
- 33. (Withdrawn) The vector of claim 32 wherein the amino acid sequence is th sequence of SEQ ID NO: 55.
- 34. (Withdrawn) The vector of claim 32 wherein said vector comprises the plasmid pCGA139-1-1.
- 35. (Withdrawn) The vector of claim 33 wherein said vector comprises the plasmid pCGA139-1-1.

2003-11-19 22:57 From-Carella, Byrne, Bain, &Gilfillan

T-343 P.007/009 F-723

Serial No. 09/900,575 Filed: 6 July 2001

- 36. (Withdrawn) A process for producing a polypeptide comprising expressing said polypeptide from a recombinant cell containing the vector of claim 34.
- 37. (Withdrawn) The process of claim 36 wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 23 to 45, and 55.
- 38. (Withdrawn The process of claim 37 wherein said polypeptide further comprises a bacterial chaperone fused to a bacterial adhesin.